Countdown 29 Days | Registration Open for CBI2026 XDC Conference – Share to Claim On-site Meal Voucher!
BoAn Biotech
Integrated Biopharmaceutical R&D and Manufacturing Company
Currently, antibody-drug conjugates (ADCs) have entered a critical phase characterized by intensive clinical advancement and commercialization. Meanwhile, emerging technological platforms such as peptide-drug conjugates (PDCs) and radionuclide-conjugated drugs are transitioning from early-stage research to clinical exploration. There is an increasingly clear demand among industry professionals for exchanges of experience across the entire development lifecycle, including target selection, clinical development, and chemistry, manufacturing, and controls (CMC) implementation.
September 4-5, 2026,【CBI 2026 Biopharmaceutical Innovation Expo – XDC Drug Development Conference】 The event will be held at Hall B, Booth B105 of the Suzhou International Expo Center. The inaugural lineup of speakers has been confirmed, bringing together industry experts from multinational pharmaceutical companies, leading domestic pharma enterprises, and emerging biotech firms in Suzhou. The two-day conference will focus on three core issues: how to select targets, how to advance clinical development, and how to navigate CMC requirements—offering practical insights and actionable strategies across the entire process, from early-stage R&D and clinical trial design to scaled-up manufacturing and regulatory submission for market approval. You are cordially invited to register and attend free of charge!
Forum Name:CBI 2026 XDC Drug Development Conference
Forum Time:September 4-5, 2026
Forum Venue:Hall B, Booth B105, Suzhou International Expo Center
Co-organizers:Auscan Biologics, PharmCube
September 4
ADC Novel Drug Discovery and Front-End Technological Innovation
[ Co-Planner ]
Dang Qun, President, ViiV Healthcare
[ Host ]
Auscan Biotech
◈ 09:30-09:55
ADC Technology and Product Portfolio Featuring Toxin Linkers with Dual Extracellular and Intracellular Cleavage Mechanisms in the Tumor Microenvironment
Cai Jiaqiang
Yilian Biologics, CSO
◈ 09:55-10:20
Next-Generation Non-Camptothecin TOPO1 Inhibitors Designed via AIDD to Address DXD-ADC Resistance
Party-Mass Affairs
ZhenShi Biopharma, President
◈ 10:20-10:45
Subject Confirmation in Progress
Lin Jun
Jianshibai Bio, General Manager
◈ 10:45-11:10
Next-Generation Bispecific Antibody ADC Platform Capable of Penetrating Biological Barriers
Xu Jian
Dili Biotech, CEO
◈ 11:10-11:50
Roundtable: Breaking the Homogenization and Involution of ADCs—Differentiated Innovation and Niche Market Layout
[ Guest ]
Cao FeiAdagene, Co-founder, President, and Acting Chief Financial Officer
Zhang YanfengBeilian Biotech, President
Zhang YijiaNovartis Search & Evaluation, Associate Director
Chen RuleiInnoLake, Co-founder & COO
◈ 11:50-13:00
Lunch Break
◈ 13:00-13:25
BoAn Biotech’s Differentiated ADC Strategy: Blue-Ocean Target (CD228) and Next-Generation ADC Development
Song Deyong
BoAn Biotech, Vice President of Innovative Research in Biologics
◈ 13:25-13:50
Systematic Evolution of the Classical Technical Pathway for Interchain Disulfide Bond Reduction/Conjugation in Antibody-Drug Conjugates (ADCs)
JiAo
Bairuiyi Biotech, CSO
◈ 13:50-14:15
Proteomics-Enabled ADC Drug Development (Proposed)
Zheng Yong
InnoMab, CEO
◈ 14:15-14:35
Roadshow
◈ 14:35-15:15
Networking & Exhibition Tour
◈ 15:15-15:40
Small Fish Empowering New Drugs: Applications and Services of Zebrafish Model Animals in New Drug Development
Li Jiqiang
Qingdao Benyue Biotech, R&D Director
◈ 15:40-16:05
Clinical Progress and Breakthroughs of XDC in Solid Tumors (Proposed)
Yang Xiugao
CSPC Pharmaceutical Group
◈ 16:05-16:30
XDC Drug: Global Regulatory Pathway from IND to Market Approval (Proposed)
Xiao Shen
Libang Pharmaceutical, Chief Scientific Officer
September 5
CMC Challenges and Commercial Manufacturing
◈ 09:30-09:55
A Brief Discussion on Quality System Design Principles and Risk Control Strategies for Innovative Drugs from R&D to Commercialization
◈ 09:55-10:20
Challenges in ADC Drug Development and CMC Regulatory Considerations
◈ 10:20-10:45
Quality Control Studies of ADC Drugs
◈ 10:45-11:10
Solutions to Challenges in ADC Process Scale-Up
◈ 11:10-11:50
Panel: Practical Strategies for Innovative Development and Production of XDCs
◈ 11:50-13:00
Lunch Break
◈ 13:00-13:25
Lifecycle Management of Process Validation for ADC Drugs
◈ 13:25-13:50
Industrial Development of PDC Drugs
◈ 13:50-14:15
GMP Manufacturing of RDC Drugs
◈ 14:15-15:00
Networking & Exhibition Tour
◈ 15:00-15:25
CMC Development Strategy for AOCs
◈ 15:25-15:50
Scale-up and Optimization of ADC Downstream Processing
◈ 15:50-16:15
ADC Process Development, Process Validation, and Marketing Authorization Application
Scan the QR Code to Register Now
Step 1:Tap [Register Now] in the lower-right corner. After successful registration, tap the [<] back button in the upper-left corner to return to the main screen.Step 2:Select the “1v1 Appointment” option on the registration mini-program page
Step 3:Click the “Guests” tab and select the guest from the list you wish to link.
Step 4:Fill out the appointment form and wait for confirmation after submission.
Note: The appointment system isApproval System,The right to interpret the review criteria is reserved by the organizer.
PharmaCircle × PharmaCircle Industry Research Institute,Leveraging over a decade of in-depth industry expertise, we are proud to unveil the 2026 White Paper Series covering seven key sub-sectors, to be officially released on-site at the 8th China Pharmaceutical Manufacturing Expo (CMC Pharma Expo) on September 4–5."White Paper on the Development of China's Innovative Drug Industry in 2026"By aggregating vast amounts of real-world industry data, case studies from leading enterprises, competitive landscape analyses, and comparisons of domestic and international policies, this publication provides authoritative data support and decision-making references for innovative pharmaceutical companies in project initiation and therapeutic area selection, CXO firms in market positioning, investment institutions in project due diligence, and pharmaceutical industrial parks in investment promotion planning. It is an indispensable annual industry reference for professionals in new drug R&D, corporate decision-makers, and industry investors.
Table of Contents↓
Registration Method: Scan the QR Code to Register“CBI2026 Biopharmaceutical Innovation Expo”+Repost this article to your WeChat Moments to claim it at the conference venue in Suzhou International Expo Center on September 4-5 (limited quantity, first come, first served).
Scan the QR Code to Register Now
Registration:
ConferenceLimited-Time Free Access(Limited spots available; registration is on a first-come, first-served basis. This registration is a pre-registration, and successful enrollment is confirmed upon approval of the application.) Accommodation and meals are at your own expense.
